Dr. Richard Gelber, Boston, Dana Farber Cancer Institute, Boston, MA/ UNITED STATES OF AMERICA
Channel: Oncoletter
Date: 01/10/2012

Vienna, ESMO 2012, Pressconference October 1:
Dr. Richard Gelber, Boston, Dana Farber Cancer Institute, Boston, MA/ UNITED STATES OF AMERICA: HERA TRIAL: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with HER2- positive early breast cancer at 8 years of median follow up